MHRA gives Nuformix’ NXP001 studies the go-ahead
The MHRA has given Nuformix approval to commence human pharmacokinetics studies with NXP001 to further assess its potential for chemotherapy-induced nausea and vomiting.
Read More
Tag: Nuformix
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
